Relapsed Follicular Lymphoma Completed Phase 2 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0041364 (Relapsed Follicular Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00715208Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular LymphomaTreatment